SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P80
Within normal range
vs 2Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 35.94% |
| Q3 2025 | 35.59% |
| Q2 2025 | 16.00% |
| Q1 2025 | 38.08% |
| Q4 2024 | -32.01% |
| Q3 2024 | -4.95% |
| Q2 2024 | 18.71% |
| Q1 2024 | -85.04% |
| Q4 2023 | 478.80% |
| Q3 2023 | 26.57% |
| Q2 2023 | -20.31% |
| Q1 2023 | 30.10% |
| Q4 2022 | -37.98% |
| Q3 2022 | -26.69% |
| Q2 2022 | -16.91% |
| Q1 2022 | -33.12% |
| Q4 2021 | 139.98% |
| Q3 2021 | 34.71% |
| Q2 2021 | -28.01% |
| Q1 2021 | 381.36% |
| Q4 2020 | 0.00% |